Skip to content
Jazz Pharmaceuticals
-
Jazz Pharmaceuticals to acquire Actio Biosciences in US$1.32B rare epilepsy deal
As part of the transaction, Actio Biosciences will establish a new privately held company dedicated to developing treatments for genetic rare neurological diseases.
-
Jazz Pharmaceuticals to withdraw Zepzelca’s second-line SCLC indication after failed trial
The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.